MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-12-2026
Stereotaxis Net Debt 2011-2026 | STXS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Stereotaxis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.98 M | -6.21 M | -14.3 M | -2.72 M | -32.6 M | -41.8 M | -25.8 M | -10.8 M | -3.69 M | -8.5 M | 12.8 M | 11.1 M | 4.76 M | 21.3 M | 24.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.5 M | -41.8 M | -5.33 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
2.38 B | $ 70.29 | 0.17 % | $ 14 B |  USA |
 |
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M | USA |
 |
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
2.46 B | $ 74.63 | 0.09 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | USA |
 |
Baxter International
BAX
|
7.55 B | $ 16.65 | -0.18 % | $ 8.54 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | USA |
 |
BioLife Solutions
BLFS
|
-88.9 M | $ 19.27 | -1.23 % | $ 888 M | USA |
 |
AtriCure
ATRC
|
-104 M | $ 29.19 | 0.41 % | $ 1.39 B | USA |
 |
electroCore
ECOR
|
-53 K | $ 7.04 | 3.53 % | $ 59.7 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
-581 K | $ 9.75 | 3.72 % | $ 23.7 M | USA |
 |
Glaukos Corporation
GKOS
|
-21.6 M | $ 116.69 | 3.48 % | $ 5.65 B | USA |
 |
Haemonetics Corporation
HAE
|
623 M | $ 58.46 | 2.87 % | $ 2.94 B | USA |
 |
Harvard Bioscience
HBIO
|
27.8 M | $ 5.53 | 6.35 % | $ 245 M | USA |
 |
ICU Medical
ICUI
|
972 M | $ 122.99 | -0.26 % | $ 3.03 B | USA |
 |
InfuSystem Holdings
INFU
|
33.3 M | $ 9.43 | 1.51 % | $ 195 M | USA |
 |
iRhythm Technologies
IRTC
|
-154 M | $ 117.22 | 0.36 % | $ 3.75 B | USA |
 |
Isoray
ISR
|
-28.4 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
-3.2 B | $ 452.58 | 0.11 % | $ 162 B | USA |
 |
Repro Med Systems
KRMD
|
-8.38 M | $ 4.26 | -1.39 % | $ 197 M | USA |
 |
LeMaitre Vascular
LMAT
|
143 M | $ 109.16 | 0.62 % | $ 2.47 B | USA |
 |
Masimo Corporation
MASI
|
572 M | $ 178.49 | -0.06 % | $ 9.51 B | USA |
 |
Microbot Medical
MBOT
|
-3.05 M | $ 2.36 | -1.67 % | $ 108 M |  Israel |
 |
Milestone Scientific
MLSS
|
-955 K | $ 0.29 | 1.9 % | $ 23.8 M | USA |
 |
Merit Medical Systems
MMSI
|
299 M | $ 67.81 | 0.16 % | $ 4.01 B | USA |
 |
Envista Holdings Corporation
NVST
|
276 M | $ 25.81 | - | $ 4.34 B | USA |
 |
Predictive Oncology
POAI
|
-9.23 M | - | - | $ 31.1 M | USA |
 |
Pro-Dex
PDEX
|
15 M | $ 48.53 | -6.08 % | $ 160 M | USA |
 |
Pulse Biosciences
PLSE
|
-73.2 M | $ 22.94 | -0.26 % | $ 1.55 B | USA |
 |
ResMed
RMD
|
513 M | $ 224.93 | 0.37 % | $ 32.9 B | USA |
 |
Retractable Technologies
RVP
|
-1.69 M | $ 0.71 | 2.98 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
-115 M | $ 20.96 | 3.71 % | $ 1.04 B | USA |
 |
STERIS plc
STE
|
1.78 B | $ 219.97 | 0.58 % | $ 21.7 B | USA |
 |
Teleflex Incorporated
TFX
|
2.26 B | $ 115.04 | -2.35 % | $ 5.13 B | USA |
 |
Utah Medical Products
UTMD
|
-60.6 M | $ 62.93 | -0.3 % | $ 204 M | USA |
 |
West Pharmaceutical Services
WST
|
-566 M | $ 256.85 | 0.8 % | $ 18.6 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.74 B | $ 11.64 | 0.09 % | $ 2.32 B | USA |
 |
AngioDynamics
ANGO
|
-48.3 M | $ 9.84 | -4.56 % | $ 402 M | USA |
 |
Becton, Dickinson and Company
BDX
|
17.1 B | $ 155.32 | 0.52 % | $ 44.7 B | USA |
 |
Nephros
NEPH
|
-2.48 M | $ 2.86 | -0.35 % | $ 29.7 M | USA |
 |
OraSure Technologies
OSUR
|
-197 M | $ 3.08 | - | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
-236 M | $ 116.95 | -0.7 % | $ 6.52 M | USA |